Image

Global Natural Killer (NK) Cell Therapeutics Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 338
  • No of Figures: 66

Global Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others) Industry Trends and Forecast to 2029.

Natural Killer (NK) Cell Therapeutics Market

Global Natural Killer (NK) Cell Therapeutics Market  Analysis and Insights

Global natural killer (NK) cell therapeutics comprises features such as an increasing need for better therapeutics options that will impair the manufacturers' launching new products into the market, enhancing its increased demand investment in research and development leads to the market growth. Currently, various research studies are taking place, which is expected to create a competitive advantage for manufacturers to develop new and innovative natural killer (NK) cell therapeutics that will provide various other opportunities in the natural killer (NK) cells therapeutics market. However, adverse side effects of therapies and unfavorable & inadequate reimbursement scenarios are expected to restrain the market growth in the forecast period.

Global natural killer (NK) cells therapeutics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. Contact us for an analyst brief to understand the analysis and the market scenario; our team will help you create a revenue impact solution to achieve your desired goal. An increase in the usage of natural killer cells for the treatment of infectious diseases is the major driver that propelled the market's demand in the forecast period.

Global natural killer (NK) cell therapeutics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that global natural killer (NK) cell therapeutics market will grow at a CAGR of 40.9% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, Others) End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others)

Countries Covered

By Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg , Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa)

Market Players Covered

Merck KGaA, Bristol-Myers Squibb Company, Glycostem, Kiadis Pharma, Cytovia Therapeutics, Nkarta, Inc., Nektar, ImmunityBio, Inc., Brink Biologics, Inc., Biohaven Pharmaceuticals, Fate Therapeutics, EMERcell, Phio Pharmaceuticals, PersonGen BioTherapeutics, Innate Pharma, Inc., INmuneBIO, Gamida Cell, Acepodia Inc., Affimed GmbH, Multimmune GmbH, iCell Gene Therapeutics, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc. among others.

Natural Killer (NK) Cell Therapeutics Market Dynamics

Drivers

  • Increase in Patient Population with Chronic Diseases

Chronic diseases generally occur in older adults that can be controlled but not cured, such as heart disease, arthritis, diabetes, stroke, or cancer. Chronic diseases are a worldwide healthcare problem concern. The change in lifestyle and physical inactivity, unhealthy diet, and tobacco use increase the burden of chronic diseases worldwide.

An increasing number of the patient population with the chronic disease led the scientist and researchers to work upon the new innovative therapeutic approach to provide patients with the best curative treatment option, which can be achieved by using natural killer (NK) cell therapy that has the potential to generate a strong immune response and has the anti-tumor capability as well.

  • Rise in Awareness about Immunotherapies

As cancer is a devastating disease and available treatment options may cause the reoccurrence of tumors, the need for the best therapeutic approach is increasing day by day. Immunotherapies have attracted much attention in recent years to treat various malignancies. Among the immunotherapies, CAR –T cell therapies have been studied and were used but have several limitations that led to the development of natural killer (NK) cell therapies. As a drug based on the natural killer (NK) cell therapeutic approach has not been approved yet, it thus needs to raise awareness among the population.

This is why several organizations and market players are launching a campaign to enhance natural killer (NK) cell therapies awareness.

Opportunities

  •  Strategic Initiatives by Market Players

Market players adopt various strategic initiatives that involve expansion, acquisition, and collaboration, among others. These initiatives help them increase the company’s product portfolio, leading to market expansion and, hence, enhancing the product demand among customers, ultimately leading the players to earn maximum revenue.

As the demand for effective and affordable natural killer (NK) cell immunotherapy is increasing worldwide, these strategic initiatives are taken by top market players aimed at enhancing business operations and earning more profitability in the market.

Restraints/Challenges

However, lack of specificity and poor in-vivo survival of the natural killer (NK) cells pose a challenge for manufacturers dealing in the market. The lack of specificity of natural killer (NK) cells targets the wrong cells, leading to ineffective treatment. The lack of specificity and poor in-vivo survival of natural killer (NK) cells also reduces the therapeutic effect of administered natural killer (NK) cell therapy.

Such a problem decreases the credibility of therapy used under clinical trial and poses challenges in front of manufacturers while getting approval.

Furthermore, various alternative treatment options are available for tumor treatment depending upon the type of tumor and the target cell. Surgery, chemotherapy, radiation therapy, hormone therapy, stem cell transplant, precision medicines, and other types of immunotherapies can be used to treat tumor treatment in place of natural killer (NK) cell therapies.

Global natural killer (NK) cell therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on natural killer (NK) cell therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In January 2022, Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors.  Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells. This acquisition help the company to to focus on R&D.
  • In December 2021, Nektar Therapeutics announced phase 1b data for novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with atopic dermatitis. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from increased levels of inflammatory T cells and reduced numbers and impaired function of immune regulating Treg cells. This has helped company to focus on R&D for further phases.

Global Natural Killer (NK) Cell Therapeutics Market

Global natural killer (NK) cell therapeutics market is categorized into five notable segments which are based on therapeutics, approaches, application, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Therapeutics

  • NK Cell Therapies
  • NK Cell Directed Antibodies

Based on therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies, and NK cell directed antibodies

  • Approaches

    • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
    • Bispecific Antibodies

Based on approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies.

  • Application

    • Cancer
    • Immunoproliferative Disorders
    • Acute Infectious Diseases
    •  Gastrointestinal Diseases
    • Others

Based on application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, immunoproliferative disorders, gastrointestinal diseases and others. Cancer is further sub-segmented into solid tumors, hematologic malignancies and others. Hematologic malignancies are further sub-segmented into multiple myeloma, acute myeloid leukemia (AML), lymphoma and others.

  • End User

    • Research & Academic Institutes
    • Hospitals
    •  Specialty Clinics

Based on end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics, and research & academic institutes

  • Distribution Channel

    • Hospital Pharmacies
    •  Direct Tender
    •  Others

Based on distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender, others.

Natural Killer (NK) Cell Therapeutics Market Regional Analysis/Insights

The natural killer (NK) cell therapeutics market is analyzed and market size insights and trends are provided by country, therapeutics, approaches, application, end-user and distribution channel as referenced above.

The countries covered in the natural killer (NK) cell therapeutics market report are U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg , Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa.

Asia-Pacific is expected to dominate due to increase in usage of natural killer (NK) cells for the treatment of cancer and infectious diseases.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Natural Killer (NK) Cell Therapeutics Market Share Analysis

Global natural killer (NK) cell therapeutics market competitive landscape provides details of the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the companies' focus on the natural killer (NK) cell therapeutics.

Some major players in the market are Merck KGaA, Bristol-Myers Squibb Company, Glycostem, Kiadis Pharma, Cytovia Therapeutics, Nkarta, Inc., Nektar, ImmunityBio, Inc., Brink Biologics, Inc., Biohaven Pharmaceuticals, Fate Therapeutics, EMERcell, Phio Pharmaceuticals, PersonGen BioTherapeutics, Innate Pharma, Inc., INmuneBIO, Gamida Cell, Acepodia Inc., Affimed GmbH, Multimmune GmbH, iCell Gene Therapeutics, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc. among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Customization Available: Global Natural Killer (NK) Cell Therapeutics Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, PIPELINE ANALYSIS

TABLE 2 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 3 GLOBAL NK CELL THERPAIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 4 GLOBAL NK CELL DIRECTED ANTIBODIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 5 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 6 GLOBAL ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 7 GLOBAL BI-SPECIFIC ANTIBODIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 8 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 9 GLOBAL CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 10 GLOBAL CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 11 GLOBAL HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 12 GLOBAL OTHERS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 13 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 14 GLOBAL HOSPITALS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 15 GLOBAL SPECIALTY CLINICS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 16 GLOBAL RESEARCH AND ACADEMIC INSTITUTES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 17 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 18 GLOBAL HOSPITAL PHARMACIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 GLOBAL DIRECT TENDER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 20 GLOBAL OTHERS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 21 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2029 (USD MILLION)

TABLE 22 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY COUNTRY, 2018-2029 (USD MILLION)

TABLE 23 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 24 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 25 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 26 NORTH AMERICA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 27 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 28 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 29 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 30 U.S. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 31 U.S. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 32 U.S. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 33 U.S. CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 34 U.S. HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 35 U.S. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 36 U.S. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 37 CANADA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 38 CANADA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 39 CANADA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 40 CANADA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 41 CANADA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 42 CANADA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 43 CANADA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 44 MEXICO NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 45 MEXICO NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 46 MEXICO NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 47 MEXICO CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 48 MEXICO HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 49 MEXICO NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 50 MEXICO NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 51 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY COUNTRY, 2018-2029 (USD MILLION)

TABLE 52 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 53 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 54 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 55 EUROPE CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 56 EUROPE HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 57 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 58 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 59 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 60 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 61 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 62 GERMANY CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 63 GERMANY HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 64 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 65 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 66 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 67 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 68 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 69 FRANCE CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 70 FRANCE HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 71 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 72 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 73 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 74 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 75 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 76 ITALY CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 77 ITALY HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 78 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 79 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 80 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 81 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 82 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 83 U.K. CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 84 U.K. HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 85 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 86 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 87 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 88 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 89 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 90 SPAIN CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 91 SPAIN HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 92 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 93 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 94 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 95 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 96 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 97 NETHERLANDS CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 98 NETHERLANDS HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 99 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 100 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 101 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 102 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 103 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 104 RUSSIA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 105 RUSSIA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 106 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 107 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 108 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 109 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 110 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 111 SWITZERLAND CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 112 SWITZERLAND HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 113 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 114 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 115 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 116 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 117 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 118 TURKEY CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 119 TURKEY HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 120 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 121 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 122 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 123 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 124 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 125 AUSTRIA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 126 AUSTRIA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 127 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 128 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 129 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 130 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 131 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 132 NORWAY CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 133 NORWAY HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 134 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 135 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 136 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 137 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 138 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 139 HUNGARY CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 140 HUNGARY HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 141 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 142 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 143 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 144 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 145 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 146 LITHUANIA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 147 LITHUANIA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 148 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 149 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 150 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 151 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 152 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 153 IRELAND CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 154 IRELAND HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 155 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 156 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 157 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 158 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 159 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 160 POLAND CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 161 POLAND HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 162 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 163 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 164 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 165 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 166 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 167 LUXEMBOURG CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 168 LUXEMBOURG HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 169 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 170 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 171 REST OF EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 172 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY COUNTRY, 2018-2029 (USD MILLION)

TABLE 173 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 174 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 175 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 176 ASIA-PACIFIC CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 177 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 178 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 179 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 180 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 181 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 182 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 183 JAPAN CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 184 JAPAN HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 185 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 186 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 187 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 188 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 189 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 190 CHINA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 191 CHINA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 192 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 193 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 194 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 195 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 196 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 197 AUSTRALIA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 198 AUSTRALIA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 199 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 200 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 201 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 202 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 203 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 204 SOUTH KOREA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 205 SOUTH KOREA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 206 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 207 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 208 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 209 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 210 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 211 INDIA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 212 INDIA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 213 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 214 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 215 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 216 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 217 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 218 SINGAPORE CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 219 SINGAPORE HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 220 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 221 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 222 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 223 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 224 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 225 MALAYSIA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 226 MALAYSIA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 227 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 228 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 229 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 230 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 231 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 232 THAILAND CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 233 THAILAND HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 234 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 235 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 236 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 237 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 238 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 239 INDONESIA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 240 INDONESIA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 241 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 242 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 243 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 244 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 245 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 246 PHILIPPINES CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 247 PHILIPPINES HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 248 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 249 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 250 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 251 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 252 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 253 VIETNAM CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 254 VIETNAM HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 255 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 256 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 257 REST OF ASIA- PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 258 SOUTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY COUNTRY, 2018-2029 (USD MILLION)

TABLE 259 SOUTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 260 SOUTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 261 SOUTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 262 SOUTH AMERICA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 263 SOUTH AMERICA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 264 SOUTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 265 SOUTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 266 BRAZIL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 267 BRAZIL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 268 BRAZIL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 269 BRAZIL CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 270 BRAZIL HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 271 BRAZIL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 272 BRAZIL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 273 ARGENTINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 274 ARGENTINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 275 ARGENTINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 276 ARGENTINA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 277 ARGENTINA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 278 ARGENTINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 279 ARGENTINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 280 PERU NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 281 PERU NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 282 PERU NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 283 PERU CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 284 PERU HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 285 PERU NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 286 PERU NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 287 REST OF SOUTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 288 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY COUNTRY, 2018-2029 (USD MILLION)

TABLE 289 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 290 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 291 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 292 MIDDLE EAST & AFRICA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 293 MIDDLE EAST & AFRICA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 294 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 295 MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 296 SAUDI ARABIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 297 SAUDI ARABIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 298 SAUDI ARABIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 299 SAUDI ARABIA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 300 SAUDI ARABIA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 301 SAUDI ARABIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 302 SAUDI ARABIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 303 SOUTH AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 304 SOUTH AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 305 SOUTH AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 306 SOUTH AFRICA CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 307 SOUTH AFRICA HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 308 SOUTH AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 309 SOUTH AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 310 U.A.E NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 311 U.A.E NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 312 U.A.E NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 313 U.A.E CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 314 U.A.E HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 315 U.A.E NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 316 U.A.E NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 317 ISRAEL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 318 ISRAEL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 319 ISRAEL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 320 ISRAEL CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 321 ISRAEL HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 322 ISRAEL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 323 ISRAEL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 324 KUWAIT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 325 KUWAIT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 326 KUWAIT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 327 KUWAIT CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 328 KUWAIT HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 329 KUWAIT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 330 KUWAIT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 331 EGYPT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

TABLE 332 EGYPT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2029 (USD MILLION)

TABLE 333 EGYPT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 334 EGYPT CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 335 EGYPT HEMATOLOGIC MALIGNANCIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2029 (USD MILLION)

TABLE 336 EGYPT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2018-2029 (USD MILLION)

TABLE 337 EGYPT NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2029 (USD MILLION)

TABLE 338 REST OF MIDDLE EAST & AFRICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

Kiadis Pharma (Netherlands), Cytovia Therapeutics (Florida), Nkarta, Inc. (US), Fate Therapeutics (US), EMERcell (France), Glycostem (Netherlands), Phio Pharmaceuticals (US), Innate Pharma, Inc. (France), INmuneBIO (US) are the Major Companies Operating in Natural Killer (NK) Cell Therapeutics Market.
The Countries Covered in the Natural Killer (NK) Cell Therapeutics Market Report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The Natural Killer (NK) Cell Therapeutics Market Report Curated by the Data Bridge Market Research Team Includes In-Depth Expert Analysis, Patient Epidemiology, Pipeline Analysis, Pricing Analysis, and Regulatory Framework.
The Natural Killer (NK) Cell Therapeutics Market will grow at a CAGR of 40.9% during the forecast by 2029.